Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @CatalystPharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CatalystPharma
-
We are proud to welcome David Ailinger as Vice President of Business Development to our
@Catalystpharma team. Learn more >>>https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-appoints-david-ailinger-vice-president …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst Pharmaceuticals announces FDA acceptance of NDA and Priority Review Status for Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS): https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-fda-acceptance-nda-and …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst Pharmaceuticals announces first patient enrolled in Phase 3 trial of Firdapse in MuSK positive myasthenia gravis (MuSK-MG) http://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-enrollment-first-patient …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst Pharmaceuticals announces NDA submission for Firdapse to the U.S. Food and Drug Administration for the treatment of Lambert-Eaton myasthenic syndrome (LEMS): http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1062314 …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst reports fourth quarter financial results: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1060928 …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst to report fourth quarter financial results and host conference call: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1060524 …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst Pharmaceuticals is pleased to announce its support for
#RareDiseaseDay 2018: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1059037 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst Pharmaceuticals announces plans to resubmit New Drug Application: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1057154 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst begins trial in Italy for patients with rare disease spinal muscular atrophy (SMA) Type 3. The trial will evaluate if amifampridine treatment can provide symptomatic relief by addressing impaired transmission at the neuromuscular junction: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1049484 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Myasthenia gravis can affect people of any age, but it's more common in women younger than 40 and in men older than 60.
#RareDiseaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst reports third quarter financial results: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1047920 …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst to report third quarter financial results and host conference call: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1046413 …
$CPRXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalyst is dedicated to delivering the first approved therapy for Lambert-Eaton myasthenic syndrome (LEMS): http://bit.ly/2uZSo7f
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lambert-Eaton myasthenic syndrome (LEMS) is a rare and debilitating disease that leads to muscle weakness and affects movement
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lambert-Eaton myasthenic syndrome (LEMS) is a progressive and life-threatening disorder. Learn more: http://bit.ly/2vtCcga
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children and families living with
#RareDisease unfortunately have one thing in common: delayed diagnosis;http://bit.ly/2vlXOugHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Proud to participate in
@GlobalGenes RARE Patient Advocacy Summit in support of patients, families & fellow advocates#2017GGSummitpic.twitter.com/H1qb1yQ8Un
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lambert-Eaton Myasthenic Syndrome is a rare autoimmune disease that can be severely disabling. Learn more: http://bit.ly/2vtCcga
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
MuSK-MG is characterized by a high incidence of respiratory crises & resistance to treatment
#myastheniagravis http://bit.ly/2ulnfI0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
MuSK-MG is an ultra-rare and debilitating neuromuscular disease.
#myastheniagravis. Learn more: http://bit.ly/2ulnfI0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.